Drug Profile
LEVI 04
Alternative Names: LEVI-04; p75NTR-FcLatest Information Update: 19 Dec 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Levicept
- Class Analgesics; Recombinant fusion proteins
- Mechanism of Action Nerve growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pain
Most Recent Events
- 13 Dec 2023 Levicept completes enrolment in its Phase-II clinical trials in Pain in Czech Republic,Denmark, Hong Kong, Moldova, Poland (IV) (NCT05618782)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Pain in United Kingdom (IV, Infusion)
- 17 Jun 2022 Phase-II clinical trials in Pain in Denmark (IV) (EudraCT2021-006540-28; 700353307)